Connect with Quotient Sciences at the 25th North American ISSX Meeting from September 10-13 in Boston, MA.
Our Senior Director of 14C Human ADME, Iain Shaw, and Adam Robinson-Miller, Senior Manager C14 Drug Development, will be there to discuss your drug development needs, including human ADME 14C radiolabeled studies for your next program. To schedule a meeting with Iain or to receive a copy of our poster after the event, please fill out the form below.
About Iain Shaw: Senior Director, 14C Enabled Drug Development
Iain Shaw is Senior Director of 14C Enabled Drug Development at Quotient Sciences. Iain has over 30 years of experience in the pharmaceutical industry, including more than 20 years of drug development experience.
Scientific Poster Spotlight: Understanding the Absorption, Metabolism, and Excretion of Masitinib in Healthy Male Subjects
At the International Society for the Study of Xenobiotics (ISSX) conference in September 2022, Quotient Sciences, AB Science, the Netherlands Organisation for Applied Scientific Research (TNO), and Pharmaron presented a poster investigating the absorption, metabolism, and excretion (ADME) of masitinib, an oral tyrosine-kinase inhibitor that targets mast cells and macrophages and is currently in development as a potential treatment for neurology, inflammatory diseases, oncology, and viral diseases.